Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines.

As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).

Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent.

In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor.

Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care.

Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

Our Products:

To date, in Canada we have three innovative medicines approved for the treatment of six rare diseases and devastating conditions.

Learn more about each of our medicines and the conditions they treat by selecting a product below.

SOLIRIS is a prescription medicine used to treat patients with PNS, aHUS and those with gMG who are AChR antibody positive and those with NMOSD who are anti-aquaporin-4 (AQP4) antibody positive.

STRENSIQ® (asfotase alfa) is the first and only prescription medicine used to treat people with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).

KANUMA is indicated for the treatment of people with a diagnosis of LAL-D and is administered as an infusion by a healthcare professional.

Contact Alexion:

Browse Additional Categories:

Go Back to EM Marketplace


Go Back to Therapeutics Royal CBD Royal CBD Creams